{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:37:18Z","timestamp":1790221038579,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005940","name":"Dansk Kraeftforsknings Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007324","name":"Sundhedsstyrelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008274","name":"PA Messerschmidt og Hustrus Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009910","name":"Hartmann Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002739","name":"Aarhus Universitets Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.canlet.2023.216480","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T12:48:32Z","timestamp":1699102112000},"page":"216480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["STING activation counters glioblastoma by vascular alteration and immune surveillance"],"prefix":"10.1016","volume":"579","author":[{"given":"Justin V.","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5824-7157","authenticated-orcid":false,"given":"Mathilde S.","family":"Blaavand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Vernejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5475-6397","authenticated-orcid":false,"given":"Rasmus W.","family":"Knopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Lindhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-2025","authenticated-orcid":false,"given":"Kristian A.","family":"Skipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esben","family":"Axelgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-3209","authenticated-orcid":false,"given":"Jacob G.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Borghammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5409-045X","authenticated-orcid":false,"given":"S\u00f8ren E.","family":"Degn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Perouzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-9190","authenticated-orcid":false,"given":"Henrik","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Kalucka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Vendelbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren R.","family":"Paludan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-7531","authenticated-orcid":false,"given":"Martin K.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.canlet.2023.216480_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2023.216480_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.canlet.2023.216480_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.canlet.2023.216480_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2017.122","article-title":"CNS cancer: glioblastoma subtypes revisited","volume":"14","author":"Sidaway","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216480_bib6","article-title":"Immunotherapy for glioblastoma: current progress and challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2023.216480_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"28","key":"10.1016\/j.canlet.2023.216480_bib9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1525243","article-title":"Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma","volume":"8","author":"Park","year":"2019","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.canlet.2023.216480_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.canlet.2023.216480_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","author":"Reardon","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.canlet.2023.216480_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.canlet.2023.216480_bib14","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","article-title":"Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function","volume":"13","author":"Fecci","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2023.216480_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216480_bib16","first-page":"454","article-title":"Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab","volume":"19","author":"Roth","year":"2017","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2023.216480_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib18","first-page":"vdac025","article-title":"Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"4","author":"Omuro","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.canlet.2023.216480_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2023.216480_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2023.216480_bib21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216480_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006976","article-title":"STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice","volume":"14","author":"Skouboe","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2023.216480_bib23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib24","article-title":"Trial watch: STING agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"28","key":"10.1016\/j.canlet.2023.216480_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.canlet.2023.216480_bib27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41388-019-1108-8","article-title":"The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma","volume":"39","author":"Thomsen","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s42003-021-02004-5","article-title":"ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance","volume":"4","author":"Jang","year":"2021","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.canlet.2023.216480_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020653","article-title":"Diffusion-weighted MRI and quantitative biophysical modeling of hippocampal neurite loss in chronic stress","volume":"6","author":"Vestergaard-Poulsen","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.canlet.2023.216480_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.3741","article-title":"White matter biomarkers from fast protocols using axially symmetric diffusion kurtosis imaging","volume":"30","author":"Hansen","year":"2017","journal-title":"NMR Biomed."},{"issue":"17","key":"10.1016\/j.canlet.2023.216480_bib32","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1111\/bph.15859","article-title":"Reelin cells and sex-dependent synaptopathology in autism following postnatal immune activation","volume":"179","author":"Ardalan","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216480_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050974","article-title":"Comparative analysis of stk11\/lkb1 versus pten deficiency in lung adenocarcinoma induced by CRISPR\/Cas9","volume":"13","author":"Berthelsen","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.canlet.2023.216480_bib34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nn.4620","article-title":"AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma","volume":"20","author":"Chow","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.canlet.2023.216480_bib35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","article-title":"Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy","volume":"30","author":"Cantelmo","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2023.216480_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41418-020-00658-y","article-title":"The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses","volume":"28","author":"Aaes","year":"2021","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.canlet.2023.216480_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Woo","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2023.216480_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20323\u2032-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.canlet.2023.216480_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccell.2022.04.009","article-title":"Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition","volume":"40","author":"Low","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.canlet.2023.216480_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2023.216480_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255536","article-title":"STING agonism turns human T cells into interferon-producing cells but impedes their functionality","volume":"24","author":"Kuhl","year":"2023","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.canlet.2023.216480_bib42","first-page":"vdac140","article-title":"T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells","volume":"4","author":"Lu","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"15","key":"10.1016\/j.canlet.2023.216480_bib43","first-page":"6","article-title":"Endothelial STING controls T cell transmigration in an IFNI-dependent manner","author":"Anastasiou","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2023.216480_bib44","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2023.216480_bib45","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1800271","article-title":"Type 1 IFN and PD-L1 coordinate lymphatic endothelial cell expansion and contraction during an inflammatory immune response","author":"Lucas","year":"2018","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.canlet.2023.216480_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2006.05.007","article-title":"PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis","volume":"45","author":"Muhlbauer","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2023.216480_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","article-title":"Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer","volume":"129","author":"Crino","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2023.216480_bib48","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2023.216480_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/neuonc\/noz015","article-title":"Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition","volume":"21","author":"Karachi","year":"2019","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216480_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(03)01018-0","article-title":"Antivascular therapy of cancer: dmxaa","volume":"4","author":"Baguley","year":"2003","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2023.216480_bib51","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.canlet.2023.216480_bib52","first-page":"14","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","author":"Park","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.canlet.2023.216480_bib53","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2023.216480_bib54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216480_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.699860","article-title":"Preoperative metastatic brain tumor-associated intracerebral hemorrhage is associated with dismal prognosis","volume":"11","author":"Hamed","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2023.216480_bib56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin. Drug Invest."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523004317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523004317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:12:57Z","timestamp":1759594377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523004317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":56,"alternative-id":["S0304383523004317"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216480","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.03.556091","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STING activation counters glioblastoma by vascular alteration and immune surveillance","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216480"}}